Literature DB >> 7554081

P53 polymorphisms and haplotypes in lung cancer.

R Birgander1, A Själander, A Rannug, A K Alexandrie, M I Sundberg, J Seidegård, G Tornling, G Beckman, L Beckman.   

Abstract

An association between the BstU I 1-1 (Pro-Pro) genotype of the p53 codon 72 polymorphism and lung cancer has previously been reported by Kawajiri et al. A reanalysis of the data by Kawajiri et al. revealed no significant difference between patients and controls with respect to allele frequencies, and the increased frequency of BstU I 1-1 homozygotes was mostly ascribable to a deviation from the Hardy-Weinberg equilibrium. In an attempt to replicate the results by Kawajiri et al. we have studied three p53 polymorphisms (BstU I and Msp I RFLPs in exon 4 and intron 6 respectively and a 16 bp duplication in intron 3) and their haplotypes in Swedish lung cancer patients and controls. The results concerning the codon 72 polymorphism were largely negative. Thus there was no significant association between lung cancer and the BstU I 1-1 type, and only a marginal difference (P = 0.044) with respect to the BstU I allele frequency when lung cancer patients were compared with patients with chronic obstructive pulmonary disease (COPD). However, when the analysis was based on haplotype frequencies larger differences appeared and it was found that only BstU I 1 (pro) alleles linked to 16 bp 1 alleles were associated with lung cancer. Pro alleles linked to the 16 bp duplication appeared instead to confer some protection against cancer. Thus the codon 72 alleles need not be functionally involved in lung cancer, but may rather be markers in linkage disequilibrium with other cancer susceptibility sites on p53.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554081     DOI: 10.1093/carcin/16.9.2233

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  30 in total

1.  DNA sequence variants of p53: cancer and aging.

Authors:  Y Sun; C Keshava; D S Sharp; A Weston; E C McCanlies
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  The p53 status in juvenile chronic arthritis and rheumatoid arthritis.

Authors:  H Taubert; B Thamm; A Meye; F Bartel; A K Rost; D Heidenreich; V John; J Brandt; M Bache; P Würl; H Schmidt; D Riemann
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

3.  Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population.

Authors:  Zhong-Zheng Zhu; Wen-Ming Cong; Shu-Fang Liu; Hui Dong; Guan-Shan Zhu; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

4.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15.

Authors:  José Luis Soto Martínez; Carmen M Cabrera Morales; Sabio Serrano Ortega; Miguel Angel López-Nevot
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

5.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

6.  International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants.

Authors:  Therese Truong; Wiebke Sauter; James D McKay; H Dean Hosgood; Carla Gallagher; Christopher I Amos; Margaret Spitz; Joshua Muscat; Philip Lazarus; Thomas Illig; H Erich Wichmann; Heike Bickeböller; Angela Risch; Hendrik Dienemann; Zuo-Feng Zhang; Behnaz Pezeshki Naeim; Ping Yang; Shanbeh Zienolddiny; Aage Haugen; Loïc Le Marchand; Yun-Chul Hong; Jin Hee Kim; Eric J Duell; Angeline S Andrew; Chikako Kiyohara; Hongbing Shen; Keitaro Matsuo; Takeshi Suzuki; Adeline Seow; Daniel P K Ng; Qing Lan; David Zaridze; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Vali Constantinescu; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Neil E Caporaso; Demetrius Albanes; Michael Thun; Maria Teresa Landi; Joanna Trubicka; Marcin Lener; Jan Lubinski; Ying Wang; Amélie Chabrier; Paolo Boffetta; Paul Brennan; Rayjean J Hung
Journal:  Carcinogenesis       Date:  2010-01-27       Impact factor: 4.944

Review 7.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

8.  CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.

Authors:  Pedro A Andrade Filho; Daisuke Ito; Albert B Deleo; Robert L Ferris
Journal:  Cancer Immunol Immunother       Date:  2010-06-25       Impact factor: 6.968

9.  P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects.

Authors:  Chao Zhou; Hao Chen; An Wang
Journal:  Tumour Biol       Date:  2013-05-30

10.  P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies.

Authors:  Shengming Dai; Chen Mao; Lijun Jiang; Guisheng Wang; Hongge Cheng
Journal:  Hum Genet       Date:  2009-04-09       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.